

# Tuesday 12 June, 2012 Panel 5 Review of Current PrEP Studies

Moderator: Carmen D. Zorrilla, MD
Professor Ob-Gyn
University of Puerto Rico
School of Medicine
carmen.zorrilla@upr,edu



### Benjamin B. Brown HPTN and IPREX

- Benjamin B. Brown is Programmes Manager for the Desmond Tutu HIV Foundation's Men's Research Division at the Faculty of Health Sciences, University of Cape Town, SA.
- He oversees research, advocacy, training, and community mobilization around HIV prevention, treatment, care, and support among key populations in Africa.

#### Roy M. Gulick, MD HPTN 069



Chief of the Division of Infectious Diseases of the Department of Medicine and Professor of Medicine at Weill Medical College of Cornell University, New York.

He is also Attending Physician at NY-Presbyterian Hospital.

His current research interests include designing, conducting, and analyzing clinical trials to evaluate antiretroviral drugs with new mechanisms of action, refine antiretroviral-therapy strategies, and test immune-based therapies.



#### Sheena McCormack, MSc Current PrEP studies: The UK



Senior Clinical Scientist, UK Medical Research Council (MRC), London, England, UK.

She is currently responsible for the Help Make History project, a network of healthy volunteers for clinical trials.

She has served as a Consultant Physician in HIV and Sexual Health and has coordinated clinical trials of interventions to prevent HIV.



# Ian McGowan, MD, PhD Pre-Exposure Prophylaxis – Not Just Oral PrEP



Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, USA.

His current areas of research are HIV-associated GI disease and microbicide development.

He is the Co-PI of the (MTN) Microbicide Trials Network.



#### Bruno Spire, MD, PhD



Research Director of the French National Institute for Medical Research, Marseille, France, and is the president of AIDS, a French HIV nongovernmental organization.

His research interests include adherence to antiretroviral treatment, determinants of quality of life in the ARV era, and sexual behaviors of patients with HIV/AIDS.

